Cantor Fitzgerald Reiterates “$19.00” Price Target for Advaxis, Inc. (NASDAQ:ADXS)
Advaxis, Inc. (NASDAQ:ADXS) has been given a $19.00 price objective by equities researchers at Cantor Fitzgerald in a report issued on Thursday. The firm currently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 196.41% from the company’s current price.
Separately, HC Wainwright set a $23.00 price target on Advaxis and gave the company a “buy” rating in a report on Monday, March 13th. Five investment analysts have rated the stock with a buy rating, Advaxis has a consensus rating of “Buy” and an average price target of $24.00.
Advaxis (NASDAQ:ADXS) traded down 4.33% on Thursday, reaching $6.41. The company had a trading volume of 848,294 shares. The stock’s 50-day moving average price is $7.58 and its 200 day moving average price is $8.20. The firm’s market capitalization is $259.36 million. Advaxis has a 52-week low of $5.70 and a 52-week high of $16.30.
A number of institutional investors have recently bought and sold shares of ADXS. Tudor Investment Corp ET AL purchased a new position in Advaxis during the first quarter worth $283,000. Schwab Charles Investment Management Inc. boosted its position in Advaxis by 6.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 128,504 shares of the biotechnology company’s stock worth $1,050,000 after buying an additional 7,353 shares during the last quarter. Geode Capital Management LLC boosted its position in Advaxis by 4.8% in the first quarter. Geode Capital Management LLC now owns 279,812 shares of the biotechnology company’s stock worth $2,286,000 after buying an additional 12,736 shares during the last quarter. Vanguard Group Inc. boosted its position in Advaxis by 9.2% in the first quarter. Vanguard Group Inc. now owns 1,663,010 shares of the biotechnology company’s stock worth $13,587,000 after buying an additional 139,710 shares during the last quarter. Finally, Marshall Wace North America L.P. purchased a new position in Advaxis during the first quarter worth $2,455,000. 55.06% of the stock is owned by institutional investors.
Advaxis Company Profile
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.